The focus of the current study was a G protein-coupled estrogen receptor (GPER)/microRNA (miR)-148a/human leukocyte antigen-G (HLA-G) signaling pathway in ovarian endometriosis. Reverse transcription-quantitative polymerase chain reaction was performed to analyze the changes in miR-148a expression. A MTT assay, flow cytometry and caspase-3/9 activity assays were performed to analyze cell proliferation, apoptosis and caspase-3/9 activity levels, respectively. Protein expression was measured using western blot analysis. In tissue samples from healthy controls, and patients with endometriosis and endometriosis-associated ovarian cancer, the expression of miR-148a was lower in in endometriosis and EAOC samples compared with healthy controls. Overexpression of miR-148a using miR mimics significantly decreased proliferation, promoted apoptosis, increased the Bcl-2 associated X apoptosis regulator (Bax)/Bcl-2 apoptosis regulator (Bcl-2) ratio and caspase3/9 activity, and suppressed HLA-G protein expression in Hs 832(C).T cells. miR-148a downregulation using miR inhibitor significantly increased cell viability, inhibited apoptosis, and reduced the Bax/Bcl-2 ratio and caspase3/9 activity, and induced HLA-G protein expression in Hs 832(C).T cells. The GPER inhibitor, G15, suppressed GPER protein expression, upregulated miR-148a expression, decreased cell proliferation, promoted apoptosis, increased the Bax/Bcl-2 ratio and caspase3 activity, and suppressed HLA-G protein expression in Hs 832(C).T cells. The findings indicate that GPER/miR-148a/HLA-G signaling pathway may mediates the development of ovarian endometriosis and may become a potential therapeutic target for the treatment of endometriosis.
G protein-coupled estrogen receptormicroRNA-148ahuman leukocyte antigen-GendometriosisapoptosisIntroduction
Endometriosis refers to a heterogeneous disease that presents as endometrial tissue with growth activity (including the glands and stroma) outside the corpus uteri and engraftment growth. Regarding the pathomorphology, it is benign (1); however, it presents malignant biological properties, such as infiltration and metastasis. The incidence rate of endometriosis is 10–15% of women (2). The epidemiological data of endometriosis reported in existing literature is incomplete since the disease can only be definitively diagnosed with laparoscopic and pathological diagnosis; however, many women do not receive laparoscopic examination if disease presents no symptoms or they are not willing to be subject to examination (3). Endometriosis can seriously affect patient quality of life, and physical and psychological health due to pelvic pain, infertility and high recurrence rate (4).
In recent years, researchers have detected that a novel form of estrogen receptor in a variety of human tissues, namely G protein-coupled receptor 30, which is also termed G protein-coupled estrogen receptor (GPER) (5). It rapidly activates signal cascade pathways in cells following binding to estrogen, generating second messengers, such as Ca2+, cyclic adenosine 3′,5′-monophosphate and nitric oxide, activate a variety of protein kinase, and regulate gene transcription. The process is termed a ‘rapid nongenomic effect’ since it only lasts for several sec or min. GPER belongs to the G protein coupled receptor protein family (6). It has no structural homology with the estrogen receptor. GPER is extensively expressed in the reproductive system, mammary glands, heart and cerebral vessels, bone and other tissues acting with estrogen (7). GPER indirectly regulates the biological functions of estrogen through a variety of signal pathways, and also can has rapid effect through directly combining with endogenous estrogen, tamoxifen and its metabolite 4-hydroxytamoxifen, environmental estrogen, specific G-1 agonists and other ligands. At present, the researches on ER in endometriosis have become quite developed (7). However, there are extremely few studies regarding GPER (7). The detection of GPER has motivated re-evaluation of the effect of estrogen in pathogenic mechanism of endometriosis. Such studies may be conducive to further reveal the physiological roles of estrogen, and also provide new avenues for developing a novel generation of drugs for the treatment of estrogen-associated diseases (8).
MicroRNAs (miRNAs) are endogenous RNA molecules (~22 nucleotides) with regulatory function discovered in eukaryotes in recent decades. Numerous miRNAs are expressed in plants, animals and viruses (9). miRNAs negatively regulate gene expression by complementary base pairing with mRNA, which leads to mRNA degradation or translation inhibition. miRNAs, as important regulatory molecules, participate in a series of important cellular, including viral defenses, hematopoietic processes, organ development, cell proliferation and apoptosis, fat metabolism and tumorigenesis (10,11).
Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex-β antigen molecule detected in 1997 (11). Under physiological conditions, HLA-G is restrictively expressed among certain tissues (11). Specific expression participates in maternal-fetal immune tolerance in extravillous trophoblasts to protect the fetus from maternal immune surveillance and immune rejection. Recent research has reported that HLA-G can restrain the activity of cytotoxic T cells, natural killer cells and other effector cells (11,12). Certain other studies have indicated that serum HLA-G levels in patients with endometriosis is higher than in individuals without endometriosis, suggesting that HLA-G may enhance the ability of ectopic endometrial cells to escape from immune surveillance, which facilitates implanting and proliferation at ectopic sites (11,13). In the current study, the role of miRNA (miR)-148a in ovarian endometriosis was explored and may be involved in the signaling pathway that induces apoptosis.
Materials and methodsHuman tissue samples and ethical approval
All healthy controls (aged 52–68; n=6), patients with endometriosis (aged 55–63; n=7) and patients with endometriosis-associated ovarian cancer (EAOC; aged 58–69; n=7) were recruited from the Reproductive Medicine Center and Department of Gynecology, Affiliated Yantai Yuhuangding Hospital of Qingdao University (Yantai, China) from June-July 2015. Endometriosis and endometriosis-associated ovarian cancer was diagnosed and confirmed by histological examination of laparoscopic biopsies. The research design was approved by the ethics committee of the Affiliated Yantai Yuhuangding Hospital of Qingdao University.
Written informed consent was obtained from each participant prior to the study. Healthy participants were diagnosed no evidence of ovarian pathology using laparoscopic biopsy due to a suspicious ovarian cyst. Endometriosis and EAOC were diagnosed, with the American Society for Reproductive Medicine stage II/III for endometriosis (14) for inclusion in this study. Endometrium tissue was collected from patients with endometriosis, tumor tissue was collected from patients with endometriosis-associated ovarian cancer and healthy tissue was collected from healthy controls. All tissue was collected during the laparoscopic surgical examination or resection. Peripheral blood was centrifuged at 1,000 × g for 10 min at 4°C and the serum was subsequently collected and stored at −80°C until further use.
Total RNA was isolated from serum or cells using TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA). cDNAs were synthesized using a Thermoscript RT kit (Thermo Fisher Scientific, Inc.) for mRNA transcripts, at 37°C for 60 min and 85°C for 5 min. qPCR was performed using a Roche LightCycler 480II Real-Time PCR System (Roche Molecular Diagnostics, Pleasanton, CA, USA) using the SensiFAST SYBR No-Rox PCR kits (Bioline Reagents Ltd, London, UK). The 2−ΔΔCq method was used to quantify mRNA expression (15).
Cell culture and cell transfection
Endometriosis cell line Hs 832(C).T from a benign ovarian cyst was purchased from Chinese Academy of Sciences, Shanghai Cell Bank (Shanghai, China) and cultured in RPMI-1640 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich; Merck KGaA) at 5% CO2 at 37°C. miR-148a mimics and negative mimics were purchased from Sangon Biotech Co., Ltd. (Shanghai, China). miR-148a mimics and negative mimics (50–100 nM) was transfected to the cells using Oligofectamine (Invitrogen; Thermo Fisher Scientific, Inc.). GPER inhibitor, G15 (100 nM, Cayman Chemical Company, Ann Arbor, MI, USA) was added to Hs 832(C).T cells transfected with miR-148a mimics after 42 h and cultured for a further 6 h.
MTT assay of cell viability
Following transfection, cells were plated at 5×103 cells/well in 96-well plates for 0, 12, 48 and 72 h. Cell viability at each time point was measured using MTT (5 mg/ml; Sigma-Aldrich; Merck KGaA) assay for 4 h at 37°C. Subsequently, dimethyl sulfoxide (5 mg/ml; Sigma-Aldrich; Merck KGaA) was added to every well after 4 h and dissolved for 20 min. Absorbance of the solution at 490 nm was read using a spectrophotometric plate reader.
Flow cytometry analysis of apoptosis
Cells were plated at 1×106 cells/well in 6-well plates. At 48 h after transfection, cells were stained with 5 ml Annexin-V and 5 ml propidium iodide (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) for 30 min at 37°C in the dark. Apoptosis was detected by flow cytometry (BD FACSCanto; BD Biosciences, Franklin Lakes, NJ, USA).
Activity assay of caspases
Cells were plated at 1×106 cells/well in 6-well plates. At 48 h after transfection, lysates were prepared using radioimmunoprecipitation assay (RIPA) buffer (Beyotime Institute of Biotechnology, Haimen, China) and protein concentration was determinate by the Coomassie blue method (Beyotime Institute of Biotechnology). The proteins (5–10 mg) were incubated with 2 mM Ac-DEVD-pNA (cat. no. C1116) or Ac-LEHD-pNA (cat. no. C1158, Beyotime Institute of Biotechnology) for 1 h at 37°C in the dark. Absorbance of the solution at 405 nm was read using a spectrophotometric plate reader.
Western blot analysis
Cells were plated at 1×106 cells/well in 6-well plates. At 48 h after transfection, lysates were prepared using RIPA buffer and protein concentration was determinate by the Coomassie blue method (Beyotime Institute of Biotechnology). The proteins (30–50 mg) were separated in 8–10% SDS-PAGE gels and then transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membrane was blocked with 5% nonfat milk at 37°C for 1 h and then incubated with anti-Bcl-2 associated X apoptosis regulator (Bax; cat. no. sc-6236; 1:500; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), Bcl-2 apoptosis regulator (Bcl-2; cat. no. sc-56015; 1:500; Santa Cruz Biotechnology, Inc.), HLA-G (cat. no. sc-53825; 1:500; Santa Cruz Biotechnology, Inc.), GPER (cat. no. ab154069; 1:1,000; Abcam) and GAPDH (cat. no. sc-25778; 1:5,000; Santa Cruz Biotechnology, Inc.) at 4°C overnight. The membrane was washed with Tris-buffered saline Tween and incubated with horseradish peroxidase conjugated anti-rabbit antibody (1:10,000; cat. no. ab97064; Abcam, Cambridge, UK) for 1 h at room temperature. The membrane was visualized using ECL reagents (Beyotime Institute of Biotechnology) and analyzed using Image-Pro Plus software (version 6.0; Media Cybernetics, Inc., Rockville, MD, USA).
Statistical analysis
Data are presented as the mean ± standard deviation of three independent experiments and was analyzed using SPSS 21.0 software (IBM Corp., Armonk, NY, USA). The Student's t-test or one-way analysis of variance followed by Tukey's post-hoc test was performed to compare experimental groups. P<0.05 was considered to indicate a statistically significant difference.
ResultsExpression of miR-148a
Healthy controls, and patients with endometriosis and EAOC were recruited in the current study. As presented in Fig. 1A, miR-148a expression of in patients with endometriosis and EAOC were significantly lower than that of healthy volunteers. Subsequently, miR-148a mimics were used to increase miR-148a expression in Hs 832(C).T cells (Fig. 1B), compared with a negative control group.
Effect of miR-148a overexpression on cell proliferation and apoptosis of Hs 832(C).T cells
Whether overexpression of miR-148a affects cell proliferation and apoptosis of Hs 832(C).T cells was analyzed using MTT and flow cytometry, respectively. Fig. 2A indicates that overexpression of miR-148a reduced cell proliferation of Hs 832(C).T cells following transfection at 12, 24 and 48 h. Overexpression of miR-148a significantly reduced proliferation of Hs 832(C).T cells compared with negative group after transfection for 48 h. Fig. 2B indicated that overexpression of miR-148a significantly induced apoptosis of Hs 832(C).T cells after transfection for 48 h compared with negative group.
Effect of miR-148a overexpression on caspase-3 and caspase-9 activity, and Bax/Bcl-2 ratio in Hs 832(C).T cells
To explore the apoptotic mechanism of miR-148a in Hs 832(C).T cells, caspase-3 and caspase-9 activity, and Bax/Bcl-2 protein expression were measured using caspase-3 and caspase-9 activity kits and western blot analysis, respectively. Fig. 3A and B demonstrated that overexpression of miR-148a significantly increased caspase-3 and caspase-9 activity in Hs 832(C).T cells after transfection for 48 h compared with the negative control group. Fig. 3C and D explained that overexpression of miR-148a significantly increased the Bax/Bcl-2 ratio in Hs 832(C).T cells after transfection for 48 h compared with the negative control group.
Effect of miR-148a overexpression on HLA-G in Hs 832(C).T cells
To further explore whether overexpression of miR-148a affects HLA-G in Hs 832(C).T cells, HLA-G protein expression was measured using western blot analysis. The results from western blot analysis demonstrated that overexpression of miR-148a significantly inhibited HLA-G protein expression in Hs 832(C).T cells after transfection for 48 h, compared with the negative control group (Fig. 4).
Effect of miR-148a inhibition on proliferation in Hs 832(C).T cells
Subsequently, an MTT assay was used to analyze the effects of miR-148a inhibition on cell viability in Hs 832(C).T cells. As demonstrated in Fig. 5, anti-miR-148a reduced miR-148a expression, and increased the proliferation of Hs 832(C).T cells.
Effect of miR-148a inhibition on caspase-3 and caspase-9 activity, and Bax/Bcl-2 ratio in Hs 832(C).T cells
To further explore the apoptotic mechanisms of miR-148a in Hs 832(C).T cells, caspase-3 and caspase-9 activity, and Bax/Bcl-2 protein expression were measured using caspase-3 and caspase-9 activity kits and western blot analysis. Inhibition of miR-148a significantly also decreased the caspase-3 and caspase-9 activities, and reduced the Bax/Bcl-2 ratio in Hs 832(C).T cells after transfection for 48 h compared with the negative control group (Fig. 6).
Effect of miR-148a inhibition on HLA-G in Hs 832(C).T cells
Western blot analysis was used to measure HLA-G protein expression Hs 832(C).T cells following miR-148a inhibition. The results from western blot analysis demonstrated that inhibition of miR-148a significantly increased HLA-G protein expression of Hs 832(C).T cells after transfection for 48 h compared with the negative group (Fig. 7).
Effect of GPER inhibition on miR-148a-induced changes to GPER and HLA-G protein expression in Hs 832(C).T cells
The role of GPER expression on the effects of miR-148a in Hs 832(C).T cells was examined. GPER inhibitor was used to reduce the expression of GPER protein. A GPER inhibitor, G15 (100 nM) was added to Hs 832 (C). As presented in Fig. 8, GPER inhibition significantly suppressed GPER and HLA-G protein expression of Hs 832(C).T cell after transfection with miR-148a, compared with transfected cells that were not treated with G15 (Fig. 8A-C). However, the inhibition of GPER significantly increased miR-148a expression in Hs 832(C).T cells transfected with miR-148a for 48 h, compared with miR-148a transfection only group (Fig. 8).
Effect of GPER inhibition on miR-148a-induced changes to cell viability and apoptosis of Hs 832(C).T cells
It was ascertained whether the suppression of GPER alters the effect of miR-148a on cell viability and apoptosis in Hs 832(C).T cells. Overexpression of miR-148a reduced cell viability and induced apoptosis of Hs 832(C).T cells; these effects were significantly intensified by the suppression of GPER using G15 in Hs 832(C).T cells, compared with the miR-148a only group (Fig. 9).
Effect of GPER inhibition on miR-148a-induced changes to caspase-3 and caspase-9 activity, and Bax/Bcl-2 ratio of Hs 832(C).T cells
Whether the suppression of GPER alters the effect of miR-148a on caspase-3 and caspase-9 activity, and the Bax/Bcl-2 ratio in Hs 832(C).T cells was determined. The suppression of GPER significantly enhanced the effect of miR-148a overexpression on caspase-3, caspase-9 and Bax/Bcl-2 ratio in Hs 832(C).T cells (Fig. 10).
Discussion
Endometriosis is a benign pathomorphological feature. However, it is an estrogen-dependent disease exhibiting malignant biological behaviors. Endometriosis is prone to occur during the childbearing period (3). The formation of endometriosis is a quite complex process involving numerous molecular events, including propagation and apoptosis of endometrial cells, migration, invasion and attaching, local hypoxia injury, inflammatory cell aggregation, formation of new vessels and remodeling of the cytoskeleton (16). Therefore, in-depth studies specific to estrogen signaling pathways and functional proteins associated with cell invasion, migration and cell apoptosis may offer novel insight into the pathogenic mechanism of endometriosis (17). These results suggest that miR-148a expression was lower in endometriosis tissue and patients with EAOC compared with healthy volunteers.
The incidence rate of endometriosis is increasing year upon year (18). However, the pathogenic mechanism is not clear. miRNAs are endogenous RNAs with regulatory function (19). Existing research indicates that miRNAs are closely associated with the development of various diseases. In addition, miRNAs have an important role in the initiation and development of endometriosis (9). In the current study, overexpression of miR-148a significantly decreased cell proliferation, promoted apoptosis, increased the Bax/Bcl-2 ratio and caspase-3/9 activity in Hs 832(C).T cells.
Analysis of estrogen-dependent tumors, such as breast and endometrial cancer, has verified that GPER can promote the invasion and migration of tumor cells through the downstream signaling pathway (5). Combining with biological functions of GPER and the estrogen dependency characteristics of endometriosis, it can be speculated that the expression of GPER is associated with the formation of ectopic foci (20). The current study reported that overexpression of miR-148a significantly inhibited HLA-G protein expression in Hs 832(C).T cells and the inhibition of GPER expression significantly increased miR-148a expression in Hs 832(C).T cells. Together, the results of these studies suggest that miR-148a may have different regulatory mechanisms of angiogenesis in endometriosis.
HLA-G is specifically expressed in extravillous trophoblasts to avoid sertoli cells being damaged by natural killer immune cells, thus to induce maternal-fetal interface to generate immune tolerance, protecting the fetus from maternal immune surveillance and immune rejection (21). It is reported in the literature that the pathological characteristics of endometriosis exhibit biological behavior similar to tumor cells, which may indicate how HLA-G protein expression in endometriotic cells promotes ectopic endometrial cells to successfully avoid immunological surveillance (22). In a previous study, HLA-G expression was detected in ectopic endometrium and glandular epithelial cells of ectopic tissue of patients with endometriosis, but no HLA-G expression was detected in normal endometrial tissue (23). Therefore, it is believed that normal endometrial tissue is different from that of patients with endometriosis, and endometrium growth on ectopia and other areas may be facilitated through the high expression of HLA-G protein, which promotes escape from immune surveillance (24). The results of the current study demonstrated that overexpression of miR-148a significantly reduced HLA-G protein expression in Hs 832(C).T cells; the inhibition of GPER activity using G15 significantly decreased cell viability, promoted apoptosis, increased Bax/Bcl-2 ratio and caspase-3 activity, and suppressed HLA-G protein expression in Hs 832(C).T cells. Together, the results demonstrate that miR-148a may negatively regulate the GPER signaling pathway in endometriosis.
In conclusion, it was identified that GPER/miR-148a/HLA-G signaling may be involved in mediating ovarian endometriosis. However, further in vivo studies of GPER/miR-148a/HLA-G are necessary in the future in order to develop novel ovarian endometriosis treatments.
Acknowledgements
Not applicable.
Funding
No funding was received.
Availability of data and materials
The analyzed data sets generated during the study are available from the corresponding author on reasonable request.
Author's contributions
YXS designed the study. SZH, JL, HCB, MMW, XRW, XH, FHL, WZ, ALX and CFH performed the experiments. SZH and YXS analyzed the data. YXS wrote the manuscript.
Ethics approval and consent to participate
The research design was approved by the ethics committee of the Affiliated Yantai Yuhuangding Hospital of Qingdao University. Written informed consent was obtained from each participant prior to the study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesChenMHuangLZhangWShiJLinXLvZZhangWLiangRJiangSMiR-23b controls TGF-β1 induced airway smooth muscle cell proliferation via TGFβR2/p-Smad3 signalsMol Immunol708493201610.1016/j.molimm.2015.12.01226748386ZhuSPanWSongXLiuYShaoXTangYLiangDHeDWangHLiuWThe microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-αNat Med1810771086201210.1038/nm.281522660635OguizaARecioCLazaroIMallaviaBBlancoJEgidoJGomez-GuerreroCPeptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetesDiabetologia5816561667201510.1007/s00125-015-3596-625982245AhmedSMundheNBorgohainMChowdhuryLKwatraMBolshetteNAhmedALahkarMDiosmin modulates the NF-kB signal transduction pathways and downregulation of various oxidative stress markers in alloxan-induced diabetic nephropathInflammation3917831797201610.1007/s10753-016-0413-427492452YuGYZhengGZChangBHuQXLinFXLiuDZWuCCDuSXLiXDNaringin stimulates osteogenic differentiation of rat bone marrow stromal cells via activation of the notch signaling pathwayStem Cells Int20167130653201610.1155/2016/7130653270694824812486CraneCAHanSJAhnBOehlkeJKivettVFedoroffAButowskiNChangSMClarkeJBergerMSIndividual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone proteinClin Cancer Res19205214201310.1158/1078-0432.CCR-11-335822872572PanEYuDYueBPotthastLChowdharySSmithPChamberlainMA prospective phase II single-institution trial of sunitinib for recurrent malignant gliomaJ Neurooncol110111118201210.1007/s11060-012-0943-z228328975735835BucknerJCShawEGPughSLChakravartiAGilbertMRBargerGRCoonsSRicciPBullardDBrownPDRadiation plus procarbazine, CCNU and vincristine in low-grade gliomaN Engl J Med37413441355201610.1056/NEJMoa1500925270502065170873KarremannMHoffmannMBeneschMKwiecienRvon BuerenAOKrammCMSecondary solid malignancies after high-grade glioma treatment in pediatric patientsPediatr Hematol Oncol32467473201510.3109/08880018.2015.105061526237586DucassouAUro-CosteEVerrellePFilleronTBenouaich-AmielALubranoVSolJCDelisleMBFavreGKenSαvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I–II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastomaEur J Cancer4921612169201310.1016/j.ejca.2013.02.03323566417BischofJWesthoffMAWagnerJEHalatschMETrentmannSKnippschildUWirtzCRBursterTCancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cellsTumour Biol391010428317692227201710.1177/101042831769222728347245MazurowskiMAClarkKCzarnekNMShamsesfandabadiPPetersKBSahaARadiogenomics of lower-grade glioma: Algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with the cancer genome atlas dataJ Neurooncol1332735201710.1007/s11060-017-2420-128470431Hernández-TiedraSFabriàsGDávilaDSalanuevaÍJCasasJMontesLRAntónZGarcía-TaboadaESalazar-RoaMLorenteMDihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilizationAutophagy1222132229201610.1080/15548627.2016.1213927276356745103338QuinlanSKennyAMedinaMEngelTJimenez-MateosEMMicroRNAs in neurodegenerative diseasesInt Rev Cell Mol Biol334309343201710.1016/bs.ircmb.2017.04.00228838542LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methodMethods25402408200110.1006/meth.2001.126211846609OhgaSShikataKYozaiKOkadaSOgawaDUsuiHWadaJShikataYMakinoHThiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activationAm J Physiol Renal Physiol292F1141F1150200710.1152/ajprenal.00288.200517190910JiangQLiuPWuXLiuWShenXLanTXuSPengJXieXHuangHBerberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: Involvement of NF-κB signaling pathwayMol Cell Endocrinol3313440201110.1016/j.mce.2010.07.02320674665LiHLCuiXLZhangJNLinSChemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factorMed Oncol3113201410.1007/s12032-014-0013-924861916BartelsUWolffJGoreLDunkelIGilheeneySAllenJGoldmanSYalonMPackerRJKoronesDNPhase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine gliomaNeuro Oncol1615541559201410.1093/neuonc/nou091248470854201068LuoXZhengXHuangHProtective effects of dexmedetomidine on brain function of glioma patients undergoing craniotomy resection and its underlying mechanismClin Neurol Neurosurg146105108201610.1016/j.clineuro.2016.05.00427206212ChenCMSyuJPWayTDHuangLJKuoSCLinCTLinCLBC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomideInt J Mol Med3612441252201510.3892/ijmm.2015.2332263293654601748DingXMaMTengJTengRKZhouSYinJFonkemEHuangJHWuEWangXExposure to ALS-FTD-CSF generates TDP-43 aggregates in glioblastoma cells through exosomes and TNTs-like structureOncotarget62417824191201510.18632/oncotarget.4680261723044695178LinCJChenTLTsengYYWuGJHsiehMHLinYWChenRMHonokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathwayToxicol Appl Pharmacol3045969201610.1016/j.taap.2016.05.01827236003LiPWangXShanQWuYWangZMicroRNA-130b promotes cell migration and invasion by inhibiting peroxisome proliferator-activated receptor-γ in human gliomaOncol Lett1326152622201710.3892/ol.2017.5760284544415403186
Expression of miR-148a. The expression of miR-148a in (A) endometriosis tissue (n=6) and (B) in Hs 832(C).T cells. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group; **P<0.01 vs. healthy tissue group. miR, microRNA; EAOC, endometriosis-associated ovarian cancer; Negative, negative control group; miR-148a, miR-148a mimics group.
Effect of miR-148a overexpression on cell viability and apoptosis of Hs 832(C).T cells. (A) Proliferation and (B) apoptosis of Hs 832(C).T cells were determined by MTT and Annexin V/propidium iodide, respectively. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. miR, microRNA; Negative, negative control group; miR-148a, miR-148a mimics group.
Effect of miR-148a overexpression on apoptosis in Hs 832(C).T cells. Overexpression of miR-148a affects (A) caspase-3 activity, (B) caspase-9 activity, and (C) Bax/Bcl-2 protein expression by western blotting with (D) densitometry analysis of Bax/Bcl-2 protein expression in Hs 832(C).T cells. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. miR, microRNA; Negative, negative control group; miR-148a, miR-148a mimics group; Bcl-2, Bcl-2 apoptosis regulator; Bax, Bcl-2 associated X apoptosis regulator.
Effect of miR-148a overexpression on HLA-G of Hs 832(C).T cells. (A) HLA-G protein expression determined western blotting with (B) densitometry analysis of HLA-G protein expression in Hs 832(C).T cells. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. HLA-G, human leukocyte antigen-G; miR, microRNA; Negative, negative control group; miR-148a, miR-148a mimics group.
Effect of miR-148a inhibitor on cell proliferation of Hs 832(C).T cells. (A) Expression of miR-148a and (B) cell proliferation of Hs 832(C).T cells were determined following transfection with miR-148a inhibitor. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. miR, microRNA; Negative, negative control group; Anti-miR-148a, anti-miR-148a mimics group.
Effect of miR-148a inhibitor on apoptosis in Hs 832(C).T cells. (A) Caspase-3 activity, (B) caspase-9 activity, (C) Bax/Bcl-2 protein expression by western blotting (D) and densitometry analysis of Bax/Bcl-2 protein expression in Hs 832(C).T cells were performed following transfection with miR-148a inhibitor. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. miR, microRNA; Negative, negative control group; Anti-miR-148a, anti-miR-148a mimics group; Bcl-2, Bcl-2 apoptosis regulator; Bax, Bcl-2 associated X apoptosis regulator.
Effect of miR-148a inhibitor on HLA-G of Hs 832(C).T cells. (A) HLA-G protein expression determined by western blotting with (B) densitometry analysis of HLA-G protein expression in Hs 832(C).T cells following transfection with miR-148a inhibitor. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. HLA-G, human leukocyte antigen-G; miR, microRNA; Negative, negative control group; miR-148a, miR-148a mimics group.
Effect of G15 on miR-148a-induced changes to GPER and HLA-G protein expression in Hs 832(C).T cells. Hs 832(C).T cells were transfected with miR-148a mimics and treated with G15. (A) GPER and HLA-G expression determined by western blotting in Hs 832(C).T cells. Densitometry analysis of (B) GPER and (C) HLA-G protein expression from western blotting. (D) Expression of miR-148a. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. ##P<0.01 vs. negative miR-148a mimics group. GPER, G protein-coupled estrogen receptor; HLA-G, human leukocyte antigen-G; miR, microRNA; Negative, negative control group; miR-148a, miR-148a mimics group; G15, GPER inhibitor group.
Effect of G15 on miR-148a-induced changes proliferation and apoptosis in Hs 832(C).T cells. Hs 832(C).T cells were transfected with miR-148a mimics and treated with G15. (A) Cell viability determined by MTT assay. (B) Apoptosis determined by Annexin V/propidium iodide staining. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. ##P<0.01 vs. negative miR-148a mimics group. miR, microRNA; Negative, negative control group; miR-148a, miR-148a mimics group; G15, GPER inhibitor group.
Effect of G15 on miR-148a-induced to caspase-3, caspase-9 and Bax/Bcl-2 rate in Hs 832(C).T cells. Hs 832(C).T cells were transfected with miR-148a mimics and treated with G15. (A) Caspase-3 and (B) caspase-9 were determined. (C) Bax/Bcl-2 rate determined by western blotting assay and (D) densitometry analysis. Data are presented as the mean ± standard deviation (n=3). **P<0.01 vs. negative control group. ##P<0.01 vs. negative miR-148a mimics group. miR, microRNA; Bax, Bcl-2 associated X apoptosis regulator; Bcl-2, Bcl-2 apoptosis regulator; Negative, negative control group; miR-148a, miR-148a mimics group; G15, GPER inhibitor group.